Economic burden of otitis media and a survey of physicians for its practice and claim codes in Korea

Chun, Byung Chul; Sohn, Woon Mok; Jung, Wonjoo; Lee, Hoan Jong

doi:10.5124/jkma.2013.56.1.62

Cited by 6 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the perpatient costs were highest in the 50–59-year-old group, which was followed by the 60–69-year-old and 40–49-year-old groups. Studies have focused on the economic costs and the prevalence of OM in children; however, few studies have focused on different age groups as in our study [ 4 , 14 , 26 , 27 ]. As far as we know, this is the first study in Korea to analyze the economic costs and the hospitalizations for OM in each age group.…”

Section: Discussionmentioning

confidence: 99%

“…Otitis media (OM) is a common middle-ear condition and is particularly common among children [ 1 , 2 ]. OM typically presents as acute OM (AOM), which is acute inflammation of Eustachian tube because of viral and bacterial infections, or as OM with effusion (OME), which is accumulation of fluid in the middle ear without acute symptoms, such as pain and fever [ 1 – 4 ]. Several studies have revealed that >80% of children experience AOM before they are 5 years old and that approximately 90% of children experience OME before they reach school age, especially 6-month-olds to 4-year-olds [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have revealed that >80% of children experience AOM before they are 5 years old and that approximately 90% of children experience OME before they reach school age, especially 6-month-olds to 4-year-olds [ 5 , 6 ]. Furthermore, a Korean study revealed that children who were <9 years old accounted for >90% of cases that required myringotomy or v-tube to treat AOM [ 4 ]. Other studies have found that recurrent AOM during early childhood is associated with Eustachian tube inefficiency and that adults with a history of childhood OM exhibit poor tube function [ 2 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…The annual economic burden of OM in the US is approximately 3–5 billion US dollars (USD), although the real cost may be higher, because of underestimated indirect costs [ 9 ]. The total cost of AOM in Korea was reported to be approximately 530.11 million USD in 2004 [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of OM among <10-year-old children was reduced by 22% after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV-7), and a further 19% reduction was observed after the introduction of PCV-13 in the UK [ 14 ]. However, in Korea, only one report has described the economic burden of OM using National Health Insurance Service (NHIS) claims data from 2003, which was before the Korean introduction of the PCVs [ 4 ]. Thus, it is unclear whether the PCVs have affected the prevalence and burden of OM in Korea.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Economic Burden of Otitis Media in Korea, 2012: A Nationally Representative Cross-Sectional Study

Kim

Lee

Park

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Background. Otitis media (OM) is a common communicable disease that is associated with a substantial economic burden. However, no Korean studies have evaluated OM-related trends after the introduction of the pneumococcal conjugate vaccines. Purpose. This study aimed to estimate the prevalence and economic burden of OM in Korea using nationally representative data. Methods. The burden of OM was estimated nationally representative data such as national health insurance claims data from 2012, based on the prevalence approach and the societal perspective. Results. In 2012, 1,788,303 patients visited medical institutions for treatment of OM, and the prevalence and burden of OM were 3.5% and 497.35 million US dollars, respectively. Patients who were 0–9 years old accounted for 59.7% of the cases and 55.2% of the total cost. Among adults, the total and perpatient costs were highest among 50–59-year-old adults. Direct medical costs and outpatient costs accounted for large proportions of the total cost (86.3% and 88.3%, resp.). Conclusion. The economic burden of OM decreased after the introduction of the pneumococcal conjugate vaccines. However, OM is still associated with a relatively large burden, especially among adults, and interventions are needed to reduce the burden of OM in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Economic Burden of Otitis Media in Korea, 2012: A Nationally Representative Cross-Sectional Study

Kim

Lee

Park

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

The change of prevalence and recurrence of acute otitis media in Korea

Kim

Jeon

Choi

et al. 2020

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Zhang¹,

Leeuwenkamp²,

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea.Methods: A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results.Results: PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option.Conclusion: Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea.

show abstract

Economic burden of otitis media and a survey of physicians for its practice and claim codes in Korea

Cited by 6 publications

References 13 publications

The Economic Burden of Otitis Media in Korea, 2012: A Nationally Representative Cross-Sectional Study

The Economic Burden of Otitis Media in Korea, 2012: A Nationally Representative Cross-Sectional Study

The change of prevalence and recurrence of acute otitis media in Korea

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Contact Info

Product

Resources

About